CDT Equity Inc. (CDT) stock forecast & analysis
0.9973
NasdaqCM · USDDelayed by 15 minutes
Down: -0.3127, -23.9%
1 analysis
Latest analysis: · verdict locked
- Open
- 1.07
- Previous close
- 1.31
- Day range
- 0.9500 – 1.08
- 52-week range
- 0.7800 – 355,000.00
- Volume (shares)
- 2.31M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 1.02M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.69
- Market cap
- 1.02M
Market Scanner’s AI analysis of CDT Equity Inc. (CDT), updated November 2026: CDT's recent analyses covered significant operating losses and bearish technical indicators alongside positive regulatory developments and strategic partnerships.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of CDT Equity Inc. (CDT) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
CDT's recent analyses covered significant operating losses and bearish technical indicators alongside positive regulatory developments and strategic partnerships.
Recent analyses for CDT Equity Inc. examined the company's financial performance, noting escalating operating and net losses from 2023 to 2025, with continued quarterly losses in 2026. Technical indicators presented a strongly bearish outlook, with the stock price significantly below its moving averages and the RSI deep in oversold territory. However, news reports highlighted positive developments including regulatory support for compounded peptides, a partnership in animal health products, and community engagement.
CDT news & sentiment
News reports highlighted positive developments for CDT, including regulatory support for compounded peptides and a new animal health partnership. Social media discussion was not covered in the provided notes.
CDT technical picture
Technical indicators for CDT Equity Inc. presented a strongly bearish outlook, with the stock price significantly below its 50-day and 200-day SMAs. Momentum readings from the RSI were deep in oversold territory, while the MACD confirmed bearish momentum, despite some buying pressure indicated by the MFI.
Fundamentals
CDT Equity Inc. has shown escalating operating and net losses from 2023 through 2025, continuing into the first half of 2026. Shareholder equity trends were also noted as negative.
Factors discussed — upside
- U.S. regulatory developments supporting expanded access to compounded peptides.
- Partnership with Manoira to explore enhancements for animal health products.
- Positive community engagement and corporate social responsibility highlighted by charitable donation.
Factors discussed — risks
- Significant increase in annual operating and net losses from 2023 to 2025.
- Continued quarterly operating and net losses in 2026.
- Stock price significantly below 50-day and 200-day SMAs.
- RSI deep in oversold territory.
- MACD below zero and trending downwards.
- Financial performance
- Technical indicators
- Regulatory developments
- Strategic partnerships
Summary updated .
CDT technical indicators
Common technical indicators for CDT, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 94.50 | Price below |
| 10-day exponential moving average | 1.93 | Price below |
| Relative strength index (14-day) | 15.22 | Oversold |
| MACD line (12/26/9) | -44.6178 | Above its signal line |
| Bollinger bands (20-day, 2σ) | -1.17 – 6.43 | Price inside the bands |
Analyses
Recent CDT.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-09 CDT.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for CDT Equity Inc.?
- Recent analyses highlighted potential upside driven by U.S. regulatory developments supporting compounded peptides, a strategic partnership with Manoira for animal health products, and positive community engagement.
- What are the risks for CDT Equity Inc.?
- Risks discussed in the analyses included escalating operating and net losses from 2023 through 2026, a strongly bearish technical outlook with the stock price significantly below key moving averages and in oversold territory, and downward trending momentum indicators.
- Is CDT Equity Inc. bullish or bearish?
- Recent AI analyses of CDT Equity Inc. examined factors on both sides. Discussed upside: Recent analyses highlighted potential upside driven by U.S. regulatory developments supporting compounded peptides, a strategic partnership with Manoira for animal health products, and positive community engagement. Discussed risks: Risks discussed in the analyses included escalating operating and net losses from 2023 through 2026, a strongly bearish technical outlook with the stock price significantly below key moving averages and in oversold territory, and downward trending momentum indicators. These are descriptive observations, not a recommendation.
- What is the latest sentiment on CDT Equity Inc.?
- News reports highlighted positive developments for CDT, including regulatory support for compounded peptides and a new animal health partnership. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse CDT Equity Inc.?
- Every analysis of CDT Equity Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for CDT Equity Inc.?
Recent analyses highlighted potential upside driven by U.S. regulatory developments supporting compounded peptides, a strategic partnership with Manoira for animal health products, and positive community engagement.
What are the risks for CDT Equity Inc.?
Risks discussed in the analyses included escalating operating and net losses from 2023 through 2026, a strongly bearish technical outlook with the stock price significantly below key moving averages and in oversold territory, and downward trending momentum indicators.
Is CDT Equity Inc. bullish or bearish?
Recent AI analyses of CDT Equity Inc. examined factors on both sides. Discussed upside: Recent analyses highlighted potential upside driven by U.S. regulatory developments supporting compounded peptides, a strategic partnership with Manoira for animal health products, and positive community engagement. Discussed risks: Risks discussed in the analyses included escalating operating and net losses from 2023 through 2026, a strongly bearish technical outlook with the stock price significantly below key moving averages and in oversold territory, and downward trending momentum indicators. These are descriptive observations, not a recommendation.
What is the latest sentiment on CDT Equity Inc.?
News reports highlighted positive developments for CDT, including regulatory support for compounded peptides and a new animal health partnership. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse CDT Equity Inc.?
Every analysis of CDT Equity Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh CDT.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.